NCT00704262CompletedPhase 2
Effect of Calcipotriol Plus Hydrocortisone Ointment on the Hypothalamic-pituitary-adrenal (HPA) Axis and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and on the Intertriginous Areas
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- LEO Pharma
- Enrollment
- 33
- Locations
- 11
- Primary Endpoint
- Change in Albumin Corrected Serum Calcium
Study Overview
Brief Summary
There are few therapies suitable for the treatment of psoriasis on the face and skin folds. As these areas are sensitive, irritation and other adverse reactions are more common than elsewhere on the body. The purpose of the study is to monitor the effect of once daily treatment for up to 8 weeks of an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g on the hypothalamic-pituitary-adrenal axis and on the calcium metabolism in patients with psoriasis vulgaris on the face and on the intertriginous areas
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Clinical diagnosis of psoriasis vulgaris involving the face and the intertriginous areas
- •Clinical diagnosis of psoriasis vulgaris on the trunk and/or limbs or earlier diagnosed with psoriasis vulgaris on the trunk and/or limbs
- •An extent of psoriatic involvement on the face of at least 5 cm2 and the sum of all facial and intertriginous lesions at least 30 cm2
- •Treatment areas (face and intertriginous) amenable to topical treatment with a maximum of 100g ointment per week
- •Disease severity of the face and intertriginous areas graded as moderate, severe or very severe according to the investigator´s global assessment of disease severity
- •Patients with a normal HPA axis function: serum cortisol concentration above 5 mcg/dl before adrenocorticotropic hormone (ACTH: tetracosactid/cosyntropin) injection and serum cortisol concentration above 18 mcg/dl 30 min after ACTH (tetracosactid/cosyntropin) injection
- •Albumin corrected serum calcium within reference range
- •Females of childbearing potential have to use a highly effective method of contraception during the study (hormonal contraceptives on oestrogen basis are not allowed)
Exclusion Criteria
- •A history of active allergy, asthma, allergic skin rash, or sensitivity to any medication (including ACTH/tetracosactid/cosyntropin) or to any component of the formulations being tested
- •Systemic treatment with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (eg vitamin D analogues, retinoids)within 2 weeks prior to Visit
- •Stable treatment with methotrexate or fumaric acid is allowed
- •Systemic treatment with corticosteroids within 12 weeks prior to Visit 1
- •Systemic use of biological treatments, whether marketed or not, directed against or with a potential effect on psoriasis vulgaris (eg. alefacept, efalizumab, etanercept, infliximab, adalimumab) within 12 weeks prior to Visit 1
- •Psoralen plus ultraviolet light A (PUVA) therapy or Grenz ray therapy within 4 weeks prior to Visit 1
- •Ultraviolet B (UVB) therapy within 2 weeks prior to Visit 1
- •Topical treatment with World Health Organization (WHO) group 2, 3 or 4 corticosteroids within 4 weeks prior to Visit 1
- •Topical treatment with WHO group 1 corticosteroids within 2 weeks prior to Visit 1
- •Any topical treatment of the face and intertriginous areas (except for emollients) within 2 weeks prior to Visit 1
- •Oestrogen therapy or any other medication known to affect cortisol levels or HPA-axis integrity within 4 weeks prior to Visit 1
- •Enzymatic inductors, systemic or topical cytochrome P450 inhibitors, hypoglycaemic sulfonamides or antidepressive medication within 4 weeks prior to Visit 1
- •Current diagnosis of erythrodermic, exfoliative, guttate or pustular psoriasis
- •Patients with any of the following conditions present on the treatment area: viral (e.g., herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, perioral dermatitis, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne rosacea, ulcers and wounds
- •Other inflammatory skin diseases (e.g., seborrhoeic dermatitis, contact dermatitis and cutaneous mycosis) that may confound the evaluation of psoriasis vulgaris on the face or on the intertriginous areas
- •Planned exposure to sun, Ultraviolet A (UVA) or UVB during the study that may affect the psoriasis vulgaris
- •Clinical signs or symptoms of Cushing´s disease or Addison's disease
- •Known or suspected severe renal insufficiency or severe hepatic disorders
- •Known or suspected disorders of calcium metabolism associated with hypercalcaemia
- •Known or suspected endocrine disorder that may affect the results of the ACTH challenge test
Arms & Interventions
Calcipotriol plus hydrocortisone (LEO 80190)
Experimental
Intervention: Calcipotriol plus hydrocortisone (LEO 80190) (Drug)
Outcomes
Primary Outcomes
Change in Albumin Corrected Serum Calcium
Time Frame: From baseline to Week 4, Week 8, and end of treatment (last value recorded i.e. Week 4, 6, or 8)
Baseline was defined as the last assessment performed before study medication application. The end of treatment data was defined as the last value recorded during the treatment phase (i.e. Week 4, 6, or 8).
The Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 30 and 60 Minutes
Time Frame: At Week 4 (Day 28) and Week 8 (Day 56)
The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) challenge test. The ACTH challenge test consisted of a baseline blood (Day -7 to Day -3) sample taken at 8 a.m. (± 30 minutes). Following the baseline blood sample, an intravenous bolus injection of 250 mcg Synacthen®/Cortrosyn® was given at Time 0 (T = 0). Serum cortisol concentrations at 30 and 60 minutes after administration were taken and reflected the stimulation induced by tetracosactid/cosyntropin. ≤18 mcg/dL was considered low.
Secondary Outcomes
- Participants With "Controlled Disease" ("Clear" or "Almost Clear") According to the Investigator's Global Assessment of Disease Severity (IGA) of the Face(At Week 4, Week 8 and end of treatment (last value recorded i.e. Week 4, 6, or 8))
- Albumin Corrected Serum Calcium(At Week 2, Week 4, Week 6 and Week 8 and end of treatment (last value recorded i.e. Week 4, 6, or 8))
- The Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 60 Minutes(At Week 4 and Week 8)
- The Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 30 Minutes(At Week 4 and Week 8)
- Serum Cortisol Concentration After 60 Minutes(At Week 4 and Week 8)
- Change in Albumin Corrected Serum Calcium(From baseline to Week 2 and Week 6)
- Serum Cortisol Concentration After 30 Minutes(At Week 4 and Week 8)
- Overall Disease Severity of Intertriginous Areas According to the IGA(At baseline, Week 2, Week 4, Week 6, Week 8, and end of treatment (last value recorded i.e. Week 4, 6, or 8))
- Albumin Corrected Serum Calcium Values Above the Upper Limit of the Reference Range(At Week 2, Week 4, Week 6 and Week 8 and end of treatment (last value recorded i.e. Week 4, 6, or 8))
- Participants With "Controlled Disease" ("Clear" or "Almost Clear") According to the IGA of the Intertriginous Areas(At Week 4, Week 8 and end of treatment (last value recorded i.e. Week 4, 6, or 8))
- Overall Disease Severity of the Face According to the IGA(At baseline, Week 2, Week 4, Week 6, Week 8, and end of treatment (last value recorded i.e. Week 4, 6, or 8))
Investigators
Study Sites (11)
Loading locations...
Similar Trials
Completed
Phase 3
Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin FoldsPsoriasis VulgarisNCT00691002LEO Pharma1,245
Active, not recruiting
Phase 1
Calcipotriol Plus Hydrocortisone in Psoriasis Vulgaris on the Face and on the Intertriginous Areas. A phase 3 study comparing an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g (LEO 80190 ointment) with calcipotriol 25 mcg/g in the ointment vehicle, hydrocortisone 10 mg/g in the ointment vehicle and the ointment vehicle alone, all applied once daily in the treatment of psoriasis vulgaris on the face and on the intertriginous areas, followed by a 52-week safety study in patients with psoriasis vulgaris on the face and on the intertriginous areas.Psoriasis vulgaris on the face and on the intertriginous areas The face is defined as: forehead including hairline, cheeks, nose, chin and ears (excluding the auditory meatus). In case of baldness or partial baldness, the forehead should be estimated considering standard or previous hairline. The intertriginous areas are defined as: 1) the axillae, 2) the genito-femoral and inguinal folds, 3) the inframammary folds, 4) the intergluteal folds and 5) the scrotum.MedDRA version: 9.1 Level: LLT Classification code 10050576 Term: Psoriasis vulgarisEUCTR2007-004782-18-GBEO Pharmaceuticals Products Ltd. A/S (LEO Pharma A/S)1,225
Active, not recruiting
Not Applicable
Calcipotriol Plus Hydrocortisone in Psoriasis Vulgarison the Face and on the Intertriginous Areas. A phase 3 study comparing an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g (LEO 80190 ointment) with calcipotriol 25 mcg/g in the ointment vehicle, hydrocortisone 10 mg/g in the ointment vehicle and the ointment vehicle alone, all applied once daily in the treatment of psoriasis vulgaris on the face and on the intertriginous areas, followed by a 52-week safety study in patients with psoriasis vulgaris on the face and on the intertriginous areas.Psoriasis vulgaris on the face and on the intertriginous areasThe face is defined as: forehead including hairline, cheeks, nose, chin and ears (excluding the auditory meatus). In case of baldness or partial baldness, the forehead should be estimated considering standard or previous hairline.The intertriginous areas are defined as: 1) the axillae, 2) the genito-femoral and inguinal folds, 3) the inframammary folds, 4) the intergluteal folds and 5) the scrotum.MedDRA version: 9.1Level: LLTClassification code 10050576Term: Psoriasis vulgarisEUCTR2007-004782-18-SIEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S)1,225
Active, not recruiting
Not Applicable
Calcipotriol Plus Hydrocortisone in Psoriasis Vulgarison the Face and on the Intertriginous Areas. A phase 3 study comparing an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g (LEO 80190 ointment) with calcipotriol 25 mcg/g in the ointment vehicle, hydrocortisone 10 mg/g in the ointment vehicle and the ointment vehicle alone, all applied once daily in the treatment of psoriasis vulgaris on the face and on the intertriginous areas, followed by a 52-week safety study in patients with psoriasis vulgaris on the face and on the intertriginous areas.Psoriasis vulgaris on the face and on the intertriginous areasThe face is defined as: forehead including hairline, cheeks, nose, chin and ears (excluding the auditory meatus). In case of baldness or partial baldness, the forehead should be estimated considering standard or previous hairline.The intertriginous areas are defined as: 1) the axillae, 2) the genito-femoral and inguinal folds, 3) the inframammary folds, 4) the intergluteal folds and 5) the scrotum.MedDRA version: 9.1Level: LLTClassification code 10050576Term: Psoriasis vulgarisEUCTR2007-004782-18-CZEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S)1,225
Active, not recruiting
Not Applicable
Calcipotriol Plus Hydrocortisone in Psoriasis Vulgarison the Face and on the Intertriginous Areas. A phase 3 study comparing an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g (LEO 80190 ointment) with calcipotriol 25 mcg/g in the ointment vehicle, hydrocortisone 10 mg/g in the ointment vehicle and the ointment vehicle alone, all applied once daily in the treatment of psoriasis vulgaris on the face and on the intertriginous areas, followed by a 52-week safety study in patients with psoriasis vulgaris on the face and on the intertriginous areas.Psoriasis vulgaris on the face and on the intertriginous areasThe face is defined as: forehead including hairline, cheeks, nose, chin and ears (excluding the auditory meatus). In case of baldness or partial baldness, the forehead should be estimated considering standard or previous hairline.The intertriginous areas are defined as: 1) the axillae, 2) the genito-femoral and inguinal folds, 3) the inframammary folds, 4) the intergluteal folds and 5) the scrotum.MedDRA version: 9.1Level: LLTClassification code 10050576Term: Psoriasis vulgarisEUCTR2007-004782-18-NLEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S)1,225